Literature DB >> 16822347

Update on Huntington's disease.

Sarah B Berman, J Timothy Greenamyre.   

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disease causing progressive movement disorders, cognitive dysfunction, and behavioral changes. Since the causative mutation of an expanded polyglutamine repeat in the huntingtin gene was identified, significant progress has been achieved in elucidating pathogenic mechanisms. This review summarizes recent developments in evaluating the role of abnormal protein aggregation, transcriptional dysregulation, mitochondrial and bioenergetic dysfunction, excitotoxicity, and abnormal cellular trafficking in the pathogenesis of HD. In addition, although therapeutic options in HD have been limited, progress in developing targeted therapies continues, and these advancements and future directions are reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822347     DOI: 10.1007/s11910-006-0019-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  58 in total

1.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

2.  Efficacy of levetiracetam in Huntington disease.

Authors:  Marina de Tommaso; Olimpia Di Fruscolo; Vittorio Sciruicchio; Nicola Specchio; Claudia Cormio; Maria Fara De Caro; Paolo Livrea
Journal:  Clin Neuropharmacol       Date:  2005 Nov-Dec       Impact factor: 1.592

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.

Authors:  Jeremy M Van Raamsdonk; Jacqueline Pearson; Daniel A Rogers; Ge Lu; Vilte E Barakauskas; Alasdair M Barr; William G Honer; Michael R Hayden; Blair R Leavitt
Journal:  Exp Neurol       Date:  2005-08-29       Impact factor: 5.330

Review 5.  The promise of minocycline in neurology.

Authors:  V Wee Yong; Jennifer Wells; Fabrizio Giuliani; Steven Casha; Christopher Power; Luanne M Metz
Journal:  Lancet Neurol       Date:  2004-12       Impact factor: 44.182

6.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.

Authors:  Brinda Ravikumar; Coralie Vacher; Zdenek Berger; Janet E Davies; Shouqing Luo; Lourdes G Oroz; Francesco Scaravilli; Douglas F Easton; Rainer Duden; Cahir J O'Kane; David C Rubinsztein
Journal:  Nat Genet       Date:  2004-05-16       Impact factor: 38.330

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

10.  CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo.

Authors:  Victor M Miller; Rick F Nelson; Cynthia M Gouvion; Aislinn Williams; Edgardo Rodriguez-Lebron; Scott Q Harper; Beverly L Davidson; Michael R Rebagliati; Henry L Paulson
Journal:  J Neurosci       Date:  2005-10-05       Impact factor: 6.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.